The announcement that AIM-listed biopesticides developer Eden Research PLC (AIM:EDEN, OTCQB:EDNSF)’s flagship fungicide product Mevalone has been added to the Organic Input List in Germany didn’t happen in a bubble.
Rather, it’s merely the latest in a long line of regulatory wins secured by the company in a couple of short years.
In January 2023, Mevalone gained approval for home garden use in Italy. This was followed by full authorisation in Poland in April and regulatory clearances in California and Florida in May. Recent updates in 2024 include additional certifications in California, Germany, and Czechia.
Significant milestone
Mevalone’s Californian approval in January was called a “significant milestone” by one analyst, not least because of the state’s prominence in wine production, where Mevalone's target disease, botrytis, is a common concern.
In June, the product, marketed as Araw in Spain, received authorisation for expanded use in the country.
Eden anticipates that the broader market for Araw will boost revenues from 2025 onward, with further details to be provided as commercialisation commences.
Cedroz, Eden’s bionematicide, also received regulatory nods in California and Florida during May 2023, further increasing its geographic footprint.
Then in September of this year, Cedroz received temporary approval for use in Greece during the 2024 growing season.
In December 2023, Ecovelex, a bird-repellent seed treatment, was temporarily approved in Italy for maize cultivation in the 2024 growing season.
That’s just to cite a few developments.
A double-edged sword
For Eden, these regulatory developments are key to determining what products it can sell and where. So when looking back through the past two years, it’s clear that the company has been no slouch in this regard.
Although regulation is the driving force behind Eden’s expanding addressable market, there’s no denying it comes with a set of headaches too.
Regulation is something of a “double-edged sword”, Eden’s chief executive Sean Smith recently told Proactive. “Regulatory is where we spend a lot of money. It's an area which slows the pace of commercial progress.
“Regulatory for us even defines our addressable market. If we have authorisation for one disease on one crop, that means that is our market. It doesn't mean we can sell that product to treat the same disease on another crop unless we get regulatory approval.”
“We love and we hate it,” Smith added. “Because at the same time, it does create opportunities. I can give you a very long list of opportunities that we are beginning to realise.”
Alongside Ecovelex and other products under development, ”there are new opportunities that have only come about because of regulatory action”, said Smith.
Just keep expanding
Eden’s near-term mission statement is clear -- keep expanding its addressable market as much as possible.
Given the lack of genuine alternatives to the product, large-scale commercialisation should be a cinch, even if regulation can be a slow and arduous process.
These protracted regulatory negotiations could be why Eden’s share price has struggled in 2024.
Year to date, shares are down 36%, reflecting still-modest top-line revenues.
But with effective products with very few competitors, a constantly expanding addressable market and more approvals on the horizon, there is undoubtedly room to grow.
Eden's AIM-listed shares were swapping for 4p with a market capitalisation of £21.3 million at the time of writing.